MAGILL ASSOCIATES, LLC

Lobbying for THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES · Government and public relations consultants

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · posted Oct 2, 2025

Lobbying activity 2

Budget/Appropriations

FY 2026 appropriations for the development of a synthetic vaccine

Medical/Disease Research/Clinical Labs

FY 2026 appropriations for the development of a synthetic vaccine

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.